PPAR? Downregulation by TGF in Fibroblast and Impaired Expression and Function in Systemic Sclerosis: A Novel Mechanism for Progressive Fibrogenesis

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Wei, Jun ^a   Ghosh, Asish K ^a   Sargent, Jennifer L ^b   Komura, Kazuhiro ^a   Wu, Minghua ^a   Huang, Qi Quan ^a   Jain, Manu ^a   Whitfield, Michael L ^b   Feghali Bostwick, Carol ^c   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; FIBROGENESIS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LUNG BIOPSY; SIGNAL TRANSDUCTION; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION; UPREGULATION; ADIPOGENESIS; ADULT; ANIMAL; CELL CULTURE; DOWN REGULATION; DRUG EFFECT; FEMALE; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; LUNG; MALE; METABOLISM; MIDDLE AGED; MOUSE; MOUSE MUTANT; NEWBORN; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; WESTERN BLOTTING;

ADIPOGENESIS; ADULT; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CELLS, CULTURED; DOWN-REGULATION; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION PROFILING; HUMANS; LUNG; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 78349281192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013778     Document Type: Article

References (65)

1. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117: 557-567.
2. Varga J, Pasche B (2009) Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5: 200-206.
3. Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, et al. (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGFbeta: involvement of Smad 3. J Invest Dermatol 112: 49-57.
4. Ghosh AK, Yuan W, Mori Y, Varga J (2000) Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 19: 3546-3555.
5. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
6. Yuan W, Varga J (2001) Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 276: 38502-38510.
7. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, et al. (2002) C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 16: 22-26.
8. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123: 993-999.
9. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77: 289-312.
10. Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771: 915-925.
11. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
12. Trojanowska M, Varga J (2007) Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 19: 568-573.
13. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, et al. (2004) Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50: 1305-1318.
14. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, et al. (2009) Peroxisome proliferator-activated receptor-{gamma} abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J.
15. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, et al. (2002) Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282: F639-648.
16. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, et al. (2005) PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288: L1146-1153.
17. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, et al. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 49: 259-263.
18. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, et al. (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940.
19. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, et al. (2002) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106: 3126-3132.
20. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2009) PPARgamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89: 47-58.
21. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, et al. (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174: 519-533.
22. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF, Jr., et al. (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715-35722.
23. Yang L, Chan CC, Kwon OS, Liu S, McGhee J, et al. (2006) Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291: G902-911.
24. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, et al. (2009) Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 129: 1243-1257.
25. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, et al. (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3: e2696.
26. Ha H, Oh EY, Lee HB (2009) The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 5: 203-211.
27. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, et al. (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17: 3091-3100.
28. Kapoor M, Kojima F, Yang L, Crofford LJ (2007) Sequential induction of proand anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 76: 103-112.
29. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, et al. (2009) A TGFbeta-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity. J Invest Dermatol.
30. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, et al. (2004) Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165: 203-217.
31. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et al. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617.
32. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, et al. (2008) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L891-901.
33. Yun Z, Maecker HL, Johnson RS, Giaccia AJ (2002) Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2: 331-341.
34. Li X, Kimura H, Hirota K, Sugimoto H, Kimura N, et al. (2007) Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferatoractivated receptor-gamma in human proximal renal tubular cells. Nephrol Dial Transplant 22: 1041-1051.
35. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, et al. (2000) Inhibition of adipogenesis by Wnt signaling. Science 289: 950-953.
36. Tan JT, McLennan SV, Song WW, Lo LW, Bonner JG, et al. (2008) Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol 295: C740-751.
37. Liu SH, Yang CN, Pan HC, Sung YJ, Liao KK, et al. IL-13 downregulates PPAR-gamma/heme oxygenase-1 via ER stress-stimulated calpain activation: aggravation of activated microglia death. Cell Mol Life Sci.
38. Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, et al. (2005) Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280: 14656-14662.
39. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, et al. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 100: 131-136.
40. Beyer C, Schett G, Gay S, Distler O, Distler JH (2009) Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 11: 220.
41. Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54: 2271-2279.
42. Dong C, Zhu S, Wang T, Yoon W, Li Z, et al. (2002) Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99: 3908-3913.
43. Culver DA, Barna BP, Raychaudhuri B, Bonfield TL, Abraham S, et al. (2004) Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 30: 1-5.
44. Kis A, Murdoch C, Zhang M, Siva A, Rodriguez-Cuenca S, et al. (2009) Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail 11: 533-541.
45. Kapoor M, McCann M, Liu S, Huh K, Denton CP, et al. (2009) Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 60: 2822-2829.
46. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, et al. (2007) Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 117: 812-822.
47. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, et al. (2007) Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56: 334-344.
48. Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, et al. (2004) Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 279: 35503-35509.
49. Fleischmajer R, Damiano V, Nedwich A (1972) Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol 105: 59-66.
50. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, et al. (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166: 1321-1332.
51. Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, et al. (2007) Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 46: 833-841.
52. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 11: 21.
53. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, et al. (2008) Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3- dependent pathways. J Hepatol 49: 758-767.
54. Psaty BM, Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356: 2522-2524.
55. Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 91: 267S-272S.
56. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, et al. (2004) Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 50: 4008-4021.
57. Hong KM, Burdick MD, Phillips RJ, Heber D, Strieter RM (2005) Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. Faseb J 19: 2029-2031.
58. Ghosh AK, Wei J, Wu M, Varga J (2008) Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun 374: 231-236.
59. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789.
60. Zheng S, Chen A (2007) Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 292: G113-123.
61. Park Y, Freedman BD, Lee EJ, Park S, Jameson JL (2003) A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 46: 365-377.
62. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, et al. (1997) Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A 94: 10669-10674.
63. Dudas M, Nagy A, Laping NJ, Moustakas A, Kaartinen V (2004) Tgf-beta3- induced palatal fusion is mediated by Alk-5/Smad pathway. Dev Biol 266: 96-108.
64. Kim S, Huang LW, Snow KJ, Ablamunits V, Hasham MG, et al. (2007) A mouse model of conditional lipodystrophy. Proc Natl Acad Sci U S A 104: 16627-16632.
65. Mori Y, Chen SJ, Varga J (2003) Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48: 1964-1978